Inhibikase Therapeutics (IKT) Return on Capital Employed Growth (1y) (2022 - 2026)
Inhibikase Therapeutics (IKT) Return on Capital Employed Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,071.81 Bn | - | 1,648.00 |
| 2 | Nanobiotix | 1,925.70 Bn | 1,925.64 Bn | - | - |
| 3 | Akari Therapeutics | 1,062.88 Bn | 1,062.88 Bn | - | 31,429.00 |
| 4 | BeOne Medicines | 469.09 Bn | 464.29 Bn | 1.35 Bn | 1,805.00 |
| 5 | Vertex Pharmaceuticals | 123.09 Bn | 115.84 Bn | 2.59 Bn | 2,503.00 |
| 6 | Regeneron Pharmaceuticals | 70.32 Bn | 61.57 Bn | 3.31 Bn | -105.00 |
| 7 | Belite Bio | 63.36 Bn | 63.36 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.71 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.69 Bn | 34.68 Bn | 959.66 Mn | 2,400.00 |
| 10 | Inhibikase Therapeutics | 410.95 Mn | 240.58 Mn | - | 1,151.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,151.00 |
| Dec 31, 2025 | 1,730.00 |
| Sep 30, 2025 | 111,821.00 |
| Jun 30, 2025 | 25,104.00 |
| Mar 31, 2025 | 19,194.00 |
| Dec 31, 2024 | 9,764.00 |
| Sep 30, 2024 | -106,890.00 |
| Jun 30, 2024 | -21,667.00 |
| Mar 31, 2024 | -15,943.00 |
| Dec 31, 2023 | -7,890.00 |
| Sep 30, 2023 | -4,816.00 |
| Dec 31, 2022 | -4,179.00 |
| Sep 30, 2022 | -4,272.00 |